0001209191-23-048222.txt : 20230905 0001209191-23-048222.hdr.sgml : 20230905 20230905173307 ACCESSION NUMBER: 0001209191-23-048222 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230901 FILED AS OF DATE: 20230905 DATE AS OF CHANGE: 20230905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shah Pratik CENTRAL INDEX KEY: 0001580787 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40288 FILM NUMBER: 231237072 MAIL ADDRESS: STREET 1: 3366 N. TORREY PINES COURT STREET 2: SUITE 220 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Design Therapeutics, Inc. CENTRAL INDEX KEY: 0001807120 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 823929248 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6005 HIDDEN VALLEY ROAD STREET 2: SUITE 110 CITY: CARLSBAD STATE: CA ZIP: 92011 BUSINESS PHONE: 858-293-4900 MAIL ADDRESS: STREET 1: 6005 HIDDEN VALLEY ROAD STREET 2: SUITE 110 CITY: CARLSBAD STATE: CA ZIP: 92011 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-01 0 0001807120 Design Therapeutics, Inc. DSGN 0001580787 Shah Pratik C/O DESIGN THERAPEUTICS, INC. 6005 HIDDEN VALLEY ROAD, SUITE 110 CARLSBAD CA 92011 1 1 0 0 President, CEO and Chairperson 0 Stock Option (right to buy) 2.48 2023-09-01 4 A 0 1050000 0.00 A 2033-08-31 Common Stock 1050000 1050000 D Stock Option (right to buy) 2.48 2023-09-01 4 A 0 525000 0.00 A 2033-08-31 Common Stock 525000 525000 D Stock Option (right to buy) 2.48 2023-09-01 4 A 0 525000 0.00 A 2033-08-31 Common Stock 525000 525000 D The shares subject to the option will vest as follows: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months. The shares subject to the option will vest as follows provided that an investigational new drug application for a product candidate for the treatment of Friedrich ataxia ("FA") submitted by the Issuer after September 1, 2023 receives clearance from the U.S. Food and Drug Administration: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months. The shares subject to the option will vest as follows provided that the Company initiates a Phase 2a clinical trial for a product candidate for the treatment of FA: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months. /s/ Mustapha Parekh, Attorney-in-Fact 2023-09-05